Healthcare / Medical Care FacilitiesTokyo
$599.00
-14.00 (-2.28%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 10%
FCF escenarios
weak_data · normalized FCF $-1.4B · quality 17.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
18.2x
↓EV/EBITDA
10.1x
↓ROE
7.6%
↑Gross Margin
13.4%
↓Debt/Equity
3.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+21.5%
FCF CAGR
—
FCF margin
-9.7%
FCF / Net income
-4.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.17B · net income $278.0M · FCF $-1.37B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.17B | $14.17B | $12.12B | $9.87B | $7.89B |
| Net Income | $278.0M | $278.0M | $639.6M | $681.9M | $454.7M |
| EBITDA | $1.60B | $1.60B | $1.97B | $1.79B | $1.40B |
| EPS | — | — | 76.19 | 84.26 | 56.27 |
| Gross Margin | 13.4% | 13.4% | 17.4% | 19.5% | 20.0% |
| Operating Margin | 6.0% | 6.0% | 10.6% | 13.0% | 12.2% |
| Net Margin | 2.0% | 2.0% | 5.3% | 6.9% | 5.8% |
| Balance Sheet | |||||
| Debt/Equity | 3.58 | 3.58 | 3.83 | 4.05 | 4.02 |
| Current Ratio | 1.49 | 1.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.37B | $-1.37B | $-2.27B | $-865.3M | $340.8M |
| Returns | |||||
| ROE | 7.6% | 7.6% | 18.6% | 25.3% | 22.6% |
| Valuation | |||||
| P/E | 18.23 | 18.23 | 18.24 | 26.53 | 42.62 |
| EV/EBITDA | 10.13 | 10.13 | 11.84 | 15.13 | 18.49 |
| P/B | 1.37 | 1.37 | 3.39 | 6.72 | 9.64 |
| Growth & Yield | |||||
| Revenue Growth | 17.0% | 17.0% | 22.7% | 25.1% | — |
| EPS Growth | — | — | -9.6% | 49.7% | — |
| Dividend Yield | 4.1% | 4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-43.0%
Start / end P/E
n/dx → n/dx
EPS bridge
76.19 → n/d
Residual
-47.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.